Increasing use of direct oral anticoagulants (DOACs) has made management of non-valvular atrial fibrillation and venous thromboembolism easier in most patients. But the presence of co-existing renal impairment could render the use of DOACs problematic because all of these drugs have varying degrees of renal excretion. In this paper we address misconceptions about the safety and efficacy of DOACs in moderate-severe renal impairment by presenting a summary of the literature from phase III trials and real-world studies. It also addresses the important consideration of correct estimate of renal function for DOAC dosing. It is hoped that the review will serve as a valuable resource for clinicians involved in anticoagulation decision-making in patients with renal impairment to guide the choice of most suitable agent. Accurate dosing is of particular relevance as registry data suggests it is done inconsistently and may be resulting in avoidable thromboembolic and bleeding events.
Direct oral anticoagulants (DOACs) have proven their efficacy in preventing thromboembolism compared to vitamin K antagonists (VKAs) with a reduced or similar risk of bleeding. They represent important advances over VKAs, with more predictable pharmacological profiles, fewer drug-drug interactions, absence of major dietary effects and lower risk of intracranial bleeding. Given that no monitoring is required and their rapid onset of action, the 2016 American College of Chest Physicians guidelines recommend DOACs as the first-line therapy to treat acute venous thromboembolism (VTE) (Kearon et al, 2016) . Similarly, the European Society of Cardiology (ESC) guidance suggests that DOACs could be used first line for patients with non-valvular atrial fibrillation (AF) .
Patients with chronic kidney disease (CKD) are at an increased of developing AF and VTE (Wattanakit et al, 2008; Albertsen et al, 2013) . These patients are also at increased risk of bleeding events compared to those with normal renal function. Bleeding risk is increased in CKD due to reduced platelet activity, reduced platelet aggregation, altered platelet and vessel wall interactions and anaemia . The increased risk of thrombosis is multifactorial but the predisposing factors include increased levels of fibrinogen, and von Willebrand factor and calcified/atherosclerosed vessel walls being less able to modulate factors that affect the coagulation cascade . The simultaneous increase in bleeding and thrombotic risk factors make anticoagulation more difficult in this population.
Although in general, DOACs may be more favourable for patients (and clinicians) due to a lack of monitoring requirements, all of the DOACs have some degree of renal excretion and thus require dose adjustment in renal impairment. This necessitates regular review of renal function in those who may have renal dysfunction to ensure the appropriate dose is being prescribed. Several phase III clinical trials for the DOACs used the exclusion criteria of creatinine clearance (CrCl) less than 25-30 ml/min in this context (Connolly et al, 2009; Schulman et al, 2009 Schulman et al, , 2014 Bauersachs et al, 2010; Granger et al, 2011; Patel et al, 2011; B€ uller et al, 2012 Agnelli et al, 2013; Giugliano et al, 2013) . Despite this, surprisingly, many DOACs are licensed for use up to a CrCl as low as 15 ml/min, even in the absence of adequate data for the effectiveness and safety in those with CrCl less than 50 ml/min. It is also important to be aware that the definitions of renal function used in the phase III DOAC trials do not fully coincide with CKD classifications (Kidney Disease: Improving Global Outcomes CKD Work p, 2013). What is also notable is the differences in licensed doses of DOACS in Europe compared to the United States (US) for different degrees of renal impairment, as shown in Table I .
In this paper we summarise the available data for the use of DOACs in those with CrCl 15-49 ml/min for different indications including AF, VTE and total hip or knee replacements (THR/TKR). For the purpose of the DOAC clinical studies, definitions of renal function are: mild impairment 50-80 ml/min, moderate impairment 30-49 ml/min and severe impairment less than 30 ml/min. This review will not cover anticoagulation in patients on dialysis, which was recently reviewed (Parker et al, 2018) .
Correct estimation of kidney function
Before initiating a DOAC, an estimate of renal function is required, firstly to ensure therapy isn't contraindicated and secondly, based on the estimate, that the appropriate dose is selected. Given that all phase III DOAC trials have reported outcomes by the Cockcroft-Gault (C-G) method for estimating CrCl, it is imperative that this formula is used in all patients who are about to be commenced on a DOAC. The C-G formula was used in clinical trials, although the newer equations, such as the Modification of Diet in Renal Disease (MDRD) and Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equations have been shown to be more accurate in determining kidney function (Levey et al, 1999 (Levey et al, , 2009 Michels et al, 2010) . The C-G CrCl requires manual calculation including patient's weight, whereas CKD-EPI and MDRD are reported in full by the laboratory and is normalised to a body surface area (BSA) of 1.73 m 2 1Á73 m 2 , which needs special consideration in those at extremes of size (Table II) . There are a number of studies comparing the differences and impact on DOAC dosing when a variety of methods are used to calculate CrCl. Kruger et al (2017) compared C-G CrCl to the CKD-EPI and MDRD formulas in 185 patients treated with DOACs. In patients with C-G CrCl <70 ml/min, the MDRD and CKD-EPI produced significantly higher results. The results for the MDRD and CKD-EPI compared to C-G CrCl were +5Á6 ml/min in patients with CrCl 30-50 ml/ min and +10Á8 ml/min in patients with CrCl 15-30 ml/min. In this study, 48% of patients with a CrCl <30 ml/min and 46% of patients with a CrCl of 30-49 ml/min would have received treatment inconsistent with current guidelines if MDRD or CKD-EPI had been used. This could have led to initiation of therapy when contraindicated or a dose reduction should have been applied (Kruger et al, 2017) . Schwartz (2016) looked at the data from the National Health and Nutrition Examination Survey (NHANES) and compared C-G CrCl with MDRD and CKD-EPI in a large population. The results were used to determine whether substituting equations would have an impact on DOAC dosing and found that 28% of subjects would have been misclassified using the CKD-EPI and MDRD estimations. For a C-G CrCl of 30-50 ml/min, both equations over-estimated renal function by around 5 ml/ min (AE13 ml/min). A correlation between C-G, CKD-EPI and MDRD improved when the latter two were corrected for body surface area (BSA) but did not reduce misclassification of dosing for those with CrCl <50 ml/min.
Age can also be a significant factor in CrCl estimation. Hellden et al (2013) calculated MDRD as well as C-G CrCl in 790 patients aged over 65 years. They found that the C-G formula estimated renal function to be lower than that of MDRD, 44Á2 AE 14Á8 ml/min versus 59Á6 AE 20Á7 ml/min/ 1Á73 m 2 (P < 0Á001). The mean difference was 13Á5 ml/min, (95% CI 12Á9-14Á2). Data simulation showed that if dabigatran had been prescribed in these participants, it would be contraindicated in 18% when using the C-G CrCl and only in 7% of those with the MDRD equation (Hellden et al, 2013) . In total, 33% of participants would be recommended full-dose dabigatran if C-G CrCl was used, whereas the corresponding percentage for MDRD would have been 67%. Similar findings were also noted by Maccallum et al (2013) . Another group looked at AF patients with heart failure prescribed DOAC therapy (Hawkins et al, 2016) . As renal function declined, C-G CrCl classified a greater proportion of patients as having moderate or severe CKD and the agreement with MDRD/ CKD-EPI declined. Moderate renal impairment was present in a quarter of patients with AF at baseline, which reduced to a third by study completion. The projected need for DOAC dose reduction was, accordingly, high. In summary, C-G CrCl should be used to estimate renal function for DOAC dosing. Other methods may lead to an over-estimation of renal function compared to C-G in those with CKD and a lack of dose adjustment may result in increased risk of major bleeding.
DOAC use in atrial fibrillation with coexisting renal impairment -the phase III trials
The phase III RE-LY (Randomized Evaluation of LongTerm Anticoagulation Therapy) study included 18,113 elderly patients, of which 19Á4% had moderate renal impairment. Exclusion criteria included CrCl <30 ml/min (Connolly et al, 2009). The study compared warfarin versus dabigatran 150 mg bd or 110 mg bd. In the moderate renal impairment subgroup, both doses showed efficacy compared to warfarin, with the 150 mg dose having a significant reduction in stroke and systemic embolism (SSE) and similar rates of major bleeding (Table III) . Notably, there was a reduced rate of intracranial haemorrhage with dabigatran (Hijazi et al, 2014) . Following on from this, the RELY-ABLE (Long term multi-centre extension of dabigatran treatment in patients with AF) trial follow-up group extended the long-term safety data and found that dabigatran 110 mg twice daily was associated with similar rates of SSE as warfarin (1Á53% vs. 1Á69%, respectively; P = 0Á34) but with lower rates of major bleeding (2Á71% vs. 3Á36%; P = 0Á003) (Connolly et al, 2013) . Based on this data, the ESC recommended that 110 mg could be considered in those individuals with risk factors for bleeding and CrCl 30-50 ml/min. The US Food and Drug Administration (FDA) did not approve the 110 mg dose due to the superiority of 150 mg dose in stroke reduction versus warfarin. The FDA sub-analysis did not find a distinct population who would benefit from the reduced bleeding risk of the 110 mg dose and felt that it was more important to ensure adequate stroke prevention (Beasley et al, 2011) . In Europe, dabigatran is not recommended in patients with a CrCl <30 ml/min due to its high renal clearance of 85% and a lack of clinical outcome data . On the other hand, the FDA approved a dose of 75 mg bd for patients with CrCl 15-30 ml/min in the US. This was on the basis of a phase I pharmacokinetic study with 11 patients who had CrCl <30 ml/min (Kooiman et al, 2016 ). An observational study by Graham et al (2016) , comparing outcomes with dabigatran and rivaroxaban in patients with AF, found an increased risk of intracranial haemorrhage and major gastrointestinal (GI) bleeds with rivaroxaban. These results were consistent when they compared the reduced renal doses of dabigatran 75 mg twice daily (n = 12 730) versus rivaroxaban 15 mg daily (n = 24 435). Rates of thromboembolic stroke were similar. Due to it being a large database study, CrCl could not be obtained so assumptions are made about appropriateness of dose reduction (Graham et al, 2016) .
The ROCKET-AF (rivaroxaban once daily oral direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation) trial included 14 264 patients with AF (Patel et al, 2011) . Exclusion criteria included patients with CrCl <30 ml/min. A reduced daily dose of rivaroxaban 15 mg daily was used in patients with moderate renal impairment, which involved 20% of the trial participants. The 2950 subjects with moderate renal impairment were found to have similar efficacy with no increased bleeding referent to warfarin (Fox et al, 2011) . A second sub-study of ROCKET-AF focused on the potential impact of worsening renal function (WRF), defined as a decrease of >20% in CrCl from screening, on the efficacy and safety of anticoagulation. A total of 3320 patients (~26%) had WRF but those treated with rivaroxaban had lower rates of SSE, without significant difference in major bleeding events, compared to patients treated with warfarin (Fordyce et al, 2016) .
The ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) trial studied 18 201 subjects. The exclusion criterion was a CrCl <25 ml/min (Granger et al, 2011) . The trial assessed the efficacy and safety of 3017 participants (15% of overall subjects), with a CrCl of 25-50 ml/min. Patients were randomized to apixaban 5 mg twice per day with dose reduction as per licensing (Table I) or warfarin. Among patients with CrCl of 25-50 ml/min, apixaban demonstrated a non-significant decreased risk for stroke and a significant decrease in the risk of bleeding compared to warfarin (Hohnloser et al, 2012) . It is important to note that only 4Á7% of patients on apixaban received a lower dose of 2Á5 mg twice daily. Because of multiple criteria for dose reduction, it is uncertain how many patients with CrCl of 25-50 ml/min received the 2Á5-mg dose and whether dose reduction affected the hazard ratio (HR) estimates. The paper also (Levey et al, 1999) •Needs to be normalised for BSA •Over-estimates renal function at low GFR compared to C-G, which may lead to a higher dose of DOAC than necessary (Hellden et al, 2013; Schwartz, 2016; Kruger et al, 2017) CKD-EPI ml/min/1Á73 m 2
• Reported by laboratory, saving clinician time • Provides the best estimate of GFR (Levey et al, 2009; Michels et al, 2010) •Needs to be normalised for BSA •Over-estimates renal function at low GFR compared to C-G, which may lead to a higher dose of DOAC than necessary (Hellden et al, 2013; Schwartz, 2016; Kruger et al, 2017) • 1Á5% per year with dabigatran 150 mg twice daily (P < 0Á01)
• HR: 0Á66; 95% CI: 0Á53-0Á82
Intracranial bleeds:
• 0Á49%, dabigatran 110 mg bd • 0Á38%, dabigatran 150 mg bd • 1Á23%, warfarin Major bleed (P = ns): HR: 0Á93; 95% CI:
ROCKET-AF (Fox et al, 2011) 2950 Rivaroxaban 15 mg od versus warfarin INR 2-3
CrCl 30-49 ml/min • 2Á32 per 100 patient-years vs. 2Á77
• HR 0Á84; 95% CI 0Á57 to 1Á23 (P = ns) Major bleeding, clinically relevant non-major bleeding and intracranial haemorrhage were similar between rivaroxaban and warfarin (P = ns)
• HR: 0Á98; 95% CI: 0Á84-1Á14 Fatal bleeding was lower with rivaroxaban (P = 0Á047)
ARISTOTLE ( • 2Á11% vs. 2Á67%
• HR 0Á79 CI 0Á55-1Á4 (P = ns) All-cause mortality:
• 7Á12% vs. 8Á3%
• HR 0Á86 CI 0Á7-1Á05
Significant benefit from reduction in major bleeding with apixaban
• HR, 0Á50; 95% CI, 0Á38-0Á66 (P = 0Á005) ENGAGE AF-TIMI 48 (Bohula et al, 2016) 2740 Edoxaban 30 mg od versus warfarin
CrCl 30-50 ml/min • HR, 0Á87; 95% CI 0Á65-1Á18 (P = 0Á94) Bleeding rates were lower at all levels of CrCl with edoxaban (P = ns). HR 0Á76 (0Á58-0Á98)
Pooled analysis (Zou et al, 2017) 12 822
DOACs versus warfarin 30-49 ml/min • RR, 0Á87; 95% CI 0Á73-1Á02; (P = 0Á009) Lower dose DOACs
• RR 1Á33; 95% CI 1Á02-1Á73 (P = 0Á04) Major bleeding per 100 patient years: DOACs 3Á49, warfarin 4Á86 (P = ns)
For major bleeding, RR 0Á79; 95% CI 0Á69-0Á89 (P = 0Á0002) Lower dose DOAC: RR 0Á86; 95% CI 0Á72-1Á03 (P = 0Á11)
Cochrane collaboration (Kimachi et al, 2017) 12 545 • HR 2Á62; 95% CI 2Á04-3Á46All-cause mortality:
• HR 0Á84; 95% CI 0Á75-0Á93
Haemorrhage: HR 2Á46; 95% CI 1Á47-4Á09 ARISTOTLE, apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation; bd, twice daily; CI, confidence interval; CKD-EPI, chronic kidney disease epidemiology collaboration; CrCl, creatinine clearance; DOAC, direct oral anticoagulant; ENGAGE AF-TIMI 48, effective anticoagulation with factor Xa next generation in atrial fibrillation-thrombolysis in myocardial infarction study 48; HR, hazard ratio; INR, international normalised ratio; ns, not significant; od, once daily; RE-LY, randomized evaluation of long-term anticoagulation therapy; ROCKET-AF, rivaroxaban once daily oral direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation; RR, relative risk. (Hijazi et al, 2016) . In the US, the dose of Apixaban is not reduced for patients with CrCl <30 ml/min, unless another dose reduction criteria is present, as there is no clinical outcome data to support dose reduction for renal function alone. Apixaban is licensed in the US also for patients on haemodialysis at a dose of 5 mg twice a day unless there is another indication to reduce the dose. The dosing recommendations for haemodialysis were based on a single-dose pharmacokinetics study in eight haemodialysis subjects matched to eight subjects with normal renal function (Wang et al, 2015) . Clinical trials are underway in this field (NCT02942407; NCT02933697) to try and provide safety and efficacy data but at present, the American College of Cardiology and ESC do not recommend its use in a dialysis population (January et al, 2014; Kirchhof et al, 2016; Steffel et al, 2018) . The ENGAGE AF-TIMI 48 (effective anticoagulation with factor Xa next generation in atrial fibrillation-thrombolysis in myocardial infarction study 48) trial looked at 14 071 patients with AF randomised to either edoxaban or warfarin (Giugliano et al, 2013) . A dose reduction was made to 30 mg daily for patients with CrCl 30-50 ml/min while those with CrCl <30 ml/min were excluded. A sub-analysis of those with moderate renal impairment (20% of trial participants) showed superior safety and comparable efficacy in the prevention of systemic embolism to warfarin (Table III; Bohula et al, 2016) . A small study from Japan looked at patients with severe renal impairment who received edoxaban 15 mg once daily (n = 50), versus patients with moderate or normal renal function who were randomized to receive either oncedaily edoxaban 30 or 60 mg (n = 22 and 21, respectively) for 12 weeks (Koretsune et al, 2015) . Plasma edoxaban concentrations and biomarkers of blood coagulation and fibrinolysis were measured. Adverse events and thromboembolic events were recorded throughout the study and no major bleeding or thromboembolic events occurred in any treatment group. Similar plasma concentrations and biomarker profiles were observed in severe renal impairment versus those with normal or moderate renal function, suggesting the 15 mg dose may be potentially effective in lower CrCl.
DOAC use in atrial fibrillation with coexisting renal impairment -beyond trials A study looking at UK patients with CKD compared warfarin versus DOACs in terms of safety and efficacy for AF concluded that DOACs and VKAs remained comparable with respect to the risk of SSE and major bleeding (Loo et al, 2018) . The overall study found DOACs were associated with a non-significantly lower risk of intracranial bleeding, as well as a higher risk of GI bleeding. Unfortunately, the study could not separate out the different DOACS to identify any differences between them. This study also used CKD-EPI, not CrCl, to estimate renal function and did not publish the degree of renal impairment. However, the real-world results from this study fit with findings from the renal sub-analyses of the major DOAC trials (Fox et al, 2011; Hohnloser et al, 2012; Hijazi et al, 2014; Bohula et al, 2016) .
A study by Kumar et al (2018) looked at bleeding and thromboembolic events in patients aged >65 years with AF and a CrCl <50 ml/min. 2434 pairs were matched using propensity scores by exposure to anticoagulant or none and followed for a median of 12 months. For patients on anticoagulation, there was an increase in ischaemic stroke and haemorrhage but reduced all-cause mortality compared with those who received no anticoagulation. The authors recommended careful consideration before starting anticoagulants in older people with CKD who develop AF. However, 72% of patients on anticoagulation in this study were prescribed warfarin; so it is likely to be less representative of the use of DOACs in this scenario.
Nielsen et al (2017) undertook a Danish registry study looking at safety and effectiveness of the reduced dose DOACs for AF. During 1 year of follow-up, low dose apixaban was associated with a higher weighted event rate of SSE (4Á8%), while dabigatran, rivaroxaban and warfarin had similar event rates of 3Á3%, 3Á5%, and 3Á7%, respectively (Nielsen et al, 2017) . Similar findings were seen at the 2Á5-year follow-up. Major bleeding was similar except for dabigatran, which had a trend towards lower bleeding. Warfarin had the highest rates of haemorrhagic stroke in both follow-up periods. Assumptions were made that dose reduction was appropriate in these patients based on the comorbidities, including CKD, increased age and extremes of weight. It is unclear if apixaban dose reduction was appropriate because it usually requires two criteria; but it does raise questions about the appropriateness of the 2Á5 mg dose in patients with AF.
A recent Cochrane review looked at DOACs versus warfarin for preventing stroke and embolism in patients with CKD and AF (Kimachi et al, 2017) . Although formally excluded from clinical trials, there was still a small number of patients (n = 390) with CrCl 15-30 ml/min, from both the ARISTOTLE and ENGAGE-TIMI trials that were reported. The findings suggested that DOACs were as effective as warfarin in reducing the rate of ischaemic stroke but were found to have lower rates of major bleeding and intracerebral bleeding (Kimachi et al, 2017) . There was a trend towards an increase in GI bleeds with DOACs. Both dabigatran and rivaroxaban were associated with a higher risk of GI bleed (Odds ratio 1Á58 and 1Á48, respectively), but not apixaban and edoxaban (Holster et al, 2013) . Ando and Capranzano (2017) suggested that high dose apixaban and edoxaban may be associated with a better clinical profile for those with moderate renal impairment. They summarised that, for AF patients with a CrCl 30-50 ml/min, the available data is strongest for dabigatran 150 mg twice daily for greatest stroke prevention versus warfarin and apixaban in its superiority of reduced major haemorrhage in comparison to warfarin (Ando & Capranzano, 2017 ). Nielsen's systematic review and meta-regression analysis of DOACs in AF patients also noted that indirect comparisons do not suggest profound differences between the DOACs, although some (e.g. apixaban and edoxaban) were associated with better safety profile in patients with moderate renal impairment (Nielsen et al, 2015) .
In a meta-analysis of DOAC studies looking at major bleeding in patients patient with AF and VTE (Raccah et al, 2016) , the DOACs were associated with a decreased risk for major bleeding compared with VKAs in patients with CrCl <50 ml/min [relative risk (RR) 0Á83 95% CI 0Á68-1Á02, P = 0.08] which was only significant for apixaban and edoxaban (apixaban RR 0Á52 95% CI 0Á40-0Á68, P < 0Á000001, edoxaban RR 0Á77 95% CI 0Á62-0Á96, P = 0.02). All DOACs significantly reduced the risk of haemorrhagic stroke compared with VKA treatment in patients with CrCl <50 ml/min (RR 0Á42 95% CI 0Á30-0Á61, P < 0Á00001). There were a small number of patients with CrCl <30 ml/min (n = 476) that were also reported in this analysis (Raccah et al, 2016) .
Summary of DOAC use in atrial fibrillation with coexisting renal impairment
In summary, DOACs are proven to be as effective as VKA in terms of reduction of SSE but with a reduced incidence of intracerebral haemorrhage and similar major bleeding in patients with moderate CKD (CrCl 30-50 ml/min). This makes them a suitable first line option for AF in these patients. Dabigatran 150 mg twice daily was associated with superior reduction in SSE versus warfarin in those with CrCl 30-49 ml/min. However, given its high renal excretion; the ESC Guidelines recommend the 110 mg dose of dabigatran could be considered in this group . In light of the potential impact of further kidney function fluctuations and deterioration, dabigatran may not be the DOAC of choice in patients with moderate CKD, especially when CrCl approaches 30 ml/min. In terms of major bleeding, apixaban has been shown to have a significant reduction compared to VKAs in this clinical setting. However, apixaban 2Á5 mg twice daily has been minimally studied in those with severe CKD and may have an increased trend toward SSE. Our review of the available literature also highlights the need for adequately powered randomised trials in severe renal impairment, i.e. CrCl 15-30 ml/min, and so close observation is warranted in this population with consideration of DOAC level monitoring (Fig 1) .
DOAC use in venous thromboembolism with coexisting renal impairment -the phase III trials
The EINSTEIN-DVT (oral rivaroxaban for symptomatic venous thromboembolism) and EINSTEIN-PE (oral rivaroxaban for the treatment of symptomatic pulmonary embolism) studies examined the effectiveness of rivaroxaban alone with subcutaneous enoxaparin followed by a VKA [target international normalised ratio (INR) 2Á0-3Á0] in preventing VTE or VTE-related death among patients with DVT and PE. Exclusion criteria for both studies included CrCl <30 ml/min (Bauersachs et al, 2010; B€ uller et al, 2012) . When looking at the sub-analyses for moderate renal impairment, rivaroxaban was shown to be as effective as standard treatment in preventing VTE recurrence -3Á4% vs. 3Á2% with enoxaparin/ VKA, but with a significant reduction in major bleeding events, 0Á9% vs. 4Á1% (Bauersachs et al, 2014) . There were 21 patients reported in the moderate renal impairment subgroup, who had a CrCl <30 ml/min but the numbers were too small to report outcomes for severe renal impairment. In a dose-finding study of rivaroxaban, no increase in risk of major bleeding was found with decreasing renal function and, as a consequence, no dose adjustments of rivaroxaban were advised for moderate renal impairment (B€ uller et al, 2008) . In a sub-analysis of data from both EINSTEIN DVT and EINSTEIN PE, an increased risk of recurrent VTE and bleeding was demonstrated with WRF. However, the standard dose of rivaroxaban was efficacious regardless of the degree of renal impairment and was associated with a significantly reduced rate of major bleeding in patients with moderate renal insufficiency compared to VKAs (Bauersachs et al, 2014) .
RE-COVER I and RE-COVER II were randomised, double-blind, double-dummy trials to compare dabigatran 150 mg twice daily with warfarin, adjusted to maintain an INR of 2Á0-3Á0 during 6 months after parenteral anticoagulation in acute VTE (Schulman et al, 2009 (Schulman et al, , 2014 . A small number of patients with moderate renal impairment (n = 245) were included in these studies. Reported outcomes for moderate renal impairment showed a trend towards reduced VTE with no significant difference in major bleeding (Schulman et al, 2014) . The overall studies found a significant reduction in major bleeding with dabigatran; however, its lack of dose reduction and high renal excretion may negate the benefit in moderate renal impairment.
In the AMPLIFY study, which compared apixaban to standard regimen as in the other trials, 6Á2% patients had moderate renal impairment. Subgroup analysis for renal function showed similar efficacy in both renal function classes (Agnelli et al, 2013) . However, both anticoagulant treatments were less effective in renally impaired patients, as shown by a 70% increase in recurrence rates compared to patients with normal renal function. In the overall analysis, apixaban significantly reduced major bleeding by 70% compared to warfarin. But this safety benefit was no longer significant in patients with moderately impaired renal functional despite lower bleeding rates (Agnelli et al, 2013) .
The Hokusai-VTE trial was a large, randomized, doubleblind, phase III trial that evaluated edoxaban versus warfarin in the treatment of acute VTE following initial treatment with a parenteral anticoagulant in 8,292 patients. There was a total of 541 patients in the moderate renal impairment subgroup and, as in the other large phase III DOAC studies, patients with a CrCl <30 ml/min were excluded (B€ uller et al, 2013) . This trial demonstrated that the reduced dose of edoxaban 30 mg daily for patients with CrCl 30 -50 ml/min maintained efficacy, including in those with severe PE, and was also safer than warfarin (Table IV) .
Van Es et al (2014) performed a meta-analysis of the DOACs in comparison to warfarin for acute VTE treatment. Overall, they found similar efficacy for all DOACs in the prevention of recurrent VTE and a significant reduction in major bleeding; a finding which was consistent in those with moderate renal impairment (Van Es et al, 2014). Jun et al (2017) undertook a real-world observational study looking at the safety of DOACs versus warfarin within the first 90 days of VTE treatment. They looked at the subgroup of CKD, defined as an estimated GFR (eGFR) <60 ml/min/1Á73 m 2 , and found no significant difference in major bleeding [HR 1Á17(0Á75-1Á77)] or mortality [HR 0Á68 (0Á36-1Á27)] however 95% of the patients on DOACs were prescribed rivaroxaban. So, this study is not necessarily representative of the DOACs as a class (Jun et al, 2017) . Unfortunately, this study does not include information on VTE recurrence. In summary, DOACS are non-inferior to VKA therapy in terms of efficacy in acute, symptomatic VTE even with moderate renal impairment. The advantage of reduced major bleeding was maintained in these patients except in the case of dabigatran. However, in patients with severe renal impairment, a lack of safety and efficacy data still is a problem, as in the case of patients with AF.
DOAC use in renal impairment and orthopaedic surgery -the trial data
Three of the DOACS are licensed for use as thromboprophylaxis in patients who have undergone THR/TKR.
A pooled analysis of the RECORD (regulation of coagulation in orthopaedic surgery to prevent deep-vein thrombosis and pulmonary embolism) phase III clinical trials suggested that age and renal function had no clinically relevant effect on the efficacy or safety profiles of rivaroxaban when used for VTE prophylaxis after major joint replacement surgery (Table V) . The mean treatment duration was 35 days in hip replacement and 12 days in patients undergoing knee replacement. No dosage adjustments were required for those with renal impairment but those with a CrCl <30 ml/min were excluded from trials. For those with moderate renal impairment, rivaroxaban was found to reduce the incidence of VTE with no difference in bleeding (Bauer et al, 2008) . The FDA analysis of RECORD 1-4 stated that that 7% of patients in these trials had CrCl <50 ml/min with 0Á5% having a CrCl <30 ml/min (Turpie et al, 2011) . In those with severe renal impairment, major or non-major clinically relevant bleeding was reported in three (10Á3%) patients in the rivaroxaban group and one (3Á6%) patient in the enoxaparin group but due to the small numbers the FDA was unable to report efficacy outcomes in this subpopulation.
In a pooled analysis of the RE-NOVATE and RE-NOVATE II (oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty), there was no difference in reduction of VTE versus enoxaparin in varying groups of renal function. In those with moderate renal function, there was an advantage for dabigatran in terms of all-cause mortality and VTE reduction (Eriksson et al, 2015) . Dahl et al (2012) found that 224 patients with moderate renal impairment who were treated with dabigatran 150 mg daily for VTE prophylaxis post-hip or -knee replacement surgery had a non-significant reduction in rate of VTE and major bleeding compared to enoxaparin. This paper would support the European Medicines Agency (EMA) recommendations that the 150 mg dabigatran dose is used for patients with CrCl <50 ml/min. Samama et al (2016) conducted an observational study to look at safety and efficacy outcomes of dabigatran in THR/TKR patients with moderate renal impairment. The median age was 80 years and 40% of patients were taking non-steroidal anti-inflammatory drugs. They found low rates of VTE and major bleeding, suggesting a good safety profile and efficacy in elderly, renally impaired patients undergoing THR or TKR (Samama et al, 2016) . These findings from the clinical practice setting add to the existing clinical trial data.
A further pooled analysis of ADVANCE-2 and 3 (apixaban dose orally versus anticoagulation with enoxaparin) trials looked at patients with moderate renal impairment, 5% total patients, taking apixaban versus enoxaparin after hip or knee arthroplasty. The results in this subgroup showed a non-significant reduction in VTE events and a trend towards increased major bleeding (Pineo et al, 2013) , Table V .
In summary, rivaroxaban is the only DOAC to show a reduction in VTE events in those with moderate renal impairment and is recommended as a first line option in the National Institute for Health and Care Excellence (NICE) guidance (NICE, 2018) . Rivaroxaban, apixaban and dabigatran showed no difference in bleeding events in those with moderate renal impairment and so the latter two are also recommended by NICE if rivaroxaban cannot be used. Very small numbers of patients with severe renal impairment were included in the outcomes reported so further safety and efficacy data is still required in this population.
Some practical considerations

Frequency of renal function monitoring
The current recommendations for measuring renal function whilst on DOACs suggests that repeat renal function tests should be done every 6 months if the patient has a CrCl between 30-60 ml/min and every 3 months if their CrCl is 15-30 ml/min (Steffel et al, 2018) . The more frequent measurement of renal function in those with pre-existing kidney impairment seems appropriate given the findings of a study by Becattini et al (2018) that renal function deterioration increased the risk of major bleeding for patients taking DOACs for AF. In this study, every absolute decrease of 1 ml/min in C-G CrCl was associated with a 2% increase in the risk of major bleeding. The clinical relevance of this finding is not negligible as more than 30% of patients had deterioration of at least one eGFR stage during the 2-year follow-up. Having a deterioration of at least one eGFR stage was associated with more than 2-fold increase in the risk for major bleeding. The authors suggest that further studies should assess whether the approach of periodic reassessment for dose reduction is associated with reduction of bleeding complications. A sub-analysis from ARISTOTLE found that worsening renal function, defined as GFR reduction >20% baseline, resulted in an increase in major bleeds, which may be related to insufficient dose adjustments (Hijazi et al, 2016) . Both these studies are in contrast to findings from the ROCKET-AF study, which found that there was renal deterioration over time but without evidence of an increase in major bleeds (Fordyce et al, 2016) . Despite renal function decline being common among patients with AF treated with oral anticoagulant agents, the DOACs have been shown to be associated with lower risks of adverse renal outcomes than warfarin. After 2 years of anticoagulant treatment, Yao et al (2017a) found that dabigatran, apixaban and rivaroxaban were associated with a reduction in the risks of acute kidney injury, decline in eGFR by ≥30% and doubling of serum creatinine compared to warfarin. The improvements in kidney function outcomes seen by DOACs were more pronounced in those patients that had experienced supratherapeutic INRs (Yao et al, 2017a) and with increasing concerns about warfarin-related nephropathy this data is reassuring for the use of DOACs. However, given that warfarin-related nephropathy is associated with over-anticoagulation causing glomerular haemorrhage and renal tubular obstruction by red blood cell casts (Brodsky et al, 2009) , this risk may not be negated if patients are over-anticoagulated with DOACs.
In summary, patients with CrCl <30 ml/min should have their renal function checked every 3 months and those CrCl 
Getting the dose right
Dose reductions were mandated predominantly based on renal function (and also on other characteristics) in the phase III trials. Emerging real-world data suggest patients prescribed DOACs are not being dosed as defined in the clinical trials (Gupta et al, 2015; Weitz & Eikelboom, 2016 ). An analysis of the SPRINT AF registry assessed the prevalence of Canadian patients eligible for the reduced dose of apixaban or rivaroxaban (Gupta et al, 2015) . This analysis suggested that more patients are being prescribed a reduced dose of the factor Xa inhibitors than those who meet eligibility criteria (Gupta et al, 2015) . Recently, a large US database study reported on outcomes relating to dosing of DOACs (Yao et al, 2017b) . Among the 1473 patients with a renal indication for dose reduction, 43Á0% were potentially overdosed, which was associated with a higher risk of major bleeding (HR 2Á19; 95% CI 1Á07-4Á46) but no statistically significant difference in stroke. Among the 13,392 patients with no renal indication for dose reduction, 13Á3% were potentially under-dosed. The under-dosing of apixaban was associated with significantly higher risk of stroke compared with standard dose when there was no renal indication for dose reduction; HR 4Á87 (95% CI 1Á30-18Á26) P = 0Á02. There was no difference in outcomes for those under-dosed who were taking dabigatran and rivaroxaban (Yao et al, 2017b) . A limitation to this database study was the use of the CKD-EPI as an estimate for renal function; however, as it would usually over-estimate renal function at low GFRs, compared to C-G, there were potentially a higher percentage of patients who were overdosed. In the ORBIT-AF registry (outcomes registry for better informed treatment of atrial fibrillation) which looked at dabigatran adoption in the US, more than one-half of the dabigatran-treated patients with CrCl <30 ml/min received 150 mg twice daily, whereas 19% of patients with CrCl > 30 ml/min received the reduced dose of 75 mg twice daily (Steinberg et al, 2013) . In a second larger analysis of the ORBIT-AF II registry looking at DOAC dosing, both apixaban and dabigatran were more likely to be under-dosed in those with moderate/severe renal impairment whereas rivaroxaban was more likely to be over-dosed. The overall findings from this study were that those under and over-dosed had increased rates of major bleeding, SSE, hospitalisation and overall mortality compared to those on the appropriate dose (Steinberg et al, 2016) . A further Danish nationwide study found similar deviations from recommended doses of dabigatran, where only 55% of patients taking 150 mg twice daily met EMA advice for dosing (Sørensen et al, 2013) . In XANTUS (xarelto for prevention of stroke in patients with atrial fibrillation), a Phase IV observational study of patients with AF prescribed rivaroxaban, more than one-third of patients with CrCl <50 ml/min received the standard dose of 20 mg daily, whereas 15% of patients with CrCl > 50 ml/min received the reduced dose (Camm et al, 2016) . There were higher incidence rates for major bleeding for the 15-mg daily dose compared with the 20-mg daily dose, with 3Á1 vs. 1Á8 events per 100 patientyears, which suggests that the 15 mg dosing decision was based on other clinical considerations.
When to consider DOAC level monitoring
The guidance from the British Committee for Standards in Haematology (BCSH) recommend monitoring of the DOAC levels in patients with renal impairment (Kitchen et al, 2014) . Although this may not be possible in all laboratories, at least currently, if a patient wishes to receive DOACs in the setting of renal impairment after considering other options, it may be reasonable to perform drug concentrations to ensure adequate levels. Diluted thrombin times that specifically use dabigatran calibrators can accurately determine dabigatran levels with linear relationship demonstrated with the drug concentration (Douxfils et al, 2015) . The anti-Xa agents (apixaban, edoxaban and rivaroxaban) require specialised anti-Xa chromogenic assays using specific drug calibrators (Barrett et al, 2010) . These assays are able to measure plasma concentrations which reach the expected levels after therapeutic doses. It would be useful to measure peak concentrations (2-4 h after drug intake) to ensure there is no excess drug circulating in the plasma, while determining trough concentrations would help to identify drug accumulation in renal impairment. The authors would use the peak and trough levels as recommended in the BCSH guidance document in this regard (Kitchen et al, 2014) . The frequency of monitoring the levels is not established but it may be considered good practice to perform repeat measurements if there is significant change in the renal function or additional drugs that may interact with the DOACs are needed. One of the key problems in this context is how to manage supratherapeutic or sub-therapeutic levels because there is no good evidence to recommend dose change based on level monitoring (Douxfils et al, 2018) . We would consider switching the DOACs to VKA in these circumstances rather than increasing or decreasing the dose.
Conclusion
In moderate renal impairment, data for DOACs in VTE and AF suggest similar efficacy to VKAs with lower rates of major bleeding. The key benefit of DOACs is the reduced risk of intracranial haemorrhage, which is always a major concern with anticoagulation and more so in those with renal impairment. These drugs are an ideal first line therapy for patients with moderate renal impairment and VTE or AF given their quick onset of action and lack of monitoring and simple dosing regimens. In the THR/TKR setting, DOACs had similar rates of thrombotic and bleeding events compared to low molecular weight hparin, so they should be considered in patients with moderate renal impairment, especially in those who can't or do not want to administer injections. There is still a distinct lack of clinical data for DOACs in those with CrCl <30 ml/min and as such these drugs should be used with caution in this population because the optimal dose has not been determined in terms of safety and efficacy outcomes. Consideration to DOAC level monitoring in this group may help to guide suitability and dosing, ensuring efficacy without accumulation. The lack of clinical data in severe renal impairment has resulted in some discrepancies of DOAC dosing in Europe and the US, which can cause confusion for clinicians. To ensure the maximal benefits, it is key to use the appropriate dose of the DOAC. In patients with renal impairment, this relies on the CrCl being calculated using the C-G formula and also on an appropriate frequency of renal function testing. As well as renal function, there are other individual factors, such as drug interactions, age and weight, that may affect the choice of DOAC dose. Based on our review of the current literature, a particular DOAC cannot be recommended in all patients with renal impairment, but we would suggest individualisation, based on patient characteristics and personal preferences, should be used to select the most appropriate DOAC.
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